| Genomic classification and prognosis in acute myeloid leukemia E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ... New England Journal of Medicine 374 (23), 2209-2221, 2016 | 4010 | 2016 |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ... New England Journal of Medicine 377 (5), 454-464, 2017 | 2179 | 2017 |
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ... New England Journal of Medicine 358 (18), 1909-1918, 2008 | 2101 | 2008 |
| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1681* | 2013 |
| Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ... New England Journal of Medicine 350 (16), 1605-1616, 2004 | 1249 | 2004 |
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene … K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ... Blood 106 (12), 3740-3746, 2005 | 1116 | 2005 |
| Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, BJ Djulbegovic, ... Jama 301 (22), 2349-2361, 2009 | 1112 | 2009 |
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML … S Fröhling, RF Schlenk, J Breitruck, A Benner, S Kreitmeier, K Tobis, ... Blood, The Journal of the American Society of Hematology 100 (13), 4372-4380, 2002 | 1098 | 2002 |
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 … P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Kroenke, L Bullinger, ... Journal of clinical oncology 28 (22), 3636-3643, 2010 | 1007 | 2010 |
| p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ... | 985 | 1995 |
| Targeting FLT3 mutations in AML: review of current knowledge and evidence N Daver, RF Schlenk, NH Russell, MJ Levis Leukemia 33 (2), 299-312, 2019 | 889 | 2019 |
| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 706 | 2012 |
| CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations S Fröhling, RF Schlenk, I Stolze, J Bihlmayr, A Benner, S Kreitmeier, ... Journal of Clinical Oncology 22 (4), 624-633, 2004 | 631 | 2004 |
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ... Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011 | 520 | 2011 |
| Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ... Journal of Clinical Oncology 29 (19), 2709-2716, 2011 | 485 | 2011 |
| The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhaeuser, ... Nature reviews Clinical oncology 9 (10), 579-590, 2012 | 474 | 2012 |
| Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further … E Taskesen, L Bullinger, A Corbacioglu, MA Sanders, CAJ Erpelinck, ... Blood, The Journal of the American Society of Hematology 117 (8), 2469-2475, 2011 | 450 | 2011 |
| Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ... Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014 | 448 | 2014 |
| Individual patient data–based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia … RF Schlenk, A Benner, J Krauter, T Buchner, C Sauerland, G Ehninger, ... Journal of Clinical Oncology 22 (18), 3741-3750, 2004 | 438 | 2004 |
| Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal … K Döhner, K Tobis, R Ulrich, S Fröhling, A Benner, RF Schlenk, ... Journal of Clinical Oncology 20 (15), 3254-3261, 2002 | 406 | 2002 |
